Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Nov 1;3(11):1050-1059.
doi: 10.1001/jamacardio.2018.3551.

Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis

Rahman Shah  1 , Sunil V Rao  2 , Samuel B Latham  1 , David E Kandzari  3
Affiliations
Meta-Analysis

Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy: A Meta-analysis

Rahman Shah et al. JAMA Cardiol. .

Abstract

Importance: A significant number of patients receive bare-metal stents (BMSs) instead of drug-eluting stents (DESs) to shorten the duration of dual antiplatelet therapy (DAPT). Emerging evidence suggests that new-generation DESs, particularly those optimized for biocompatibility, may be more efficacious and safer than BMSs, even with a single month of DAPT after stent implantation.

Objective: To evaluate the efficacy and safety of DESs compared with BMSs for coronary intervention with a single month of DAPT.

Data sources: Human studies found in PubMed, the Cochrane databases through April 2018, and reference lists of selected articles.

Study selection: Randomized clinical trials were included if they enrolled patients undergoing percutaneous coronary intervention and randomly assigned each patient to treatment with either DESs or BMSs. The additional inclusion criterion was use of only 1 month of DAPT poststent implantation.

Data extraction and synthesis: Two reviewers independently extracted the data. Odds ratios (ORs) were calculated using random-effects models.

Main outcomes and measures: The efficacy end points were major adverse cardiac events, myocardial infarction, target vessel revascularization, ischemia-driven target lesion revascularization, cardiac mortality, and all-cause mortality at 1 year. The safety outcomes were stent thrombosis and bleeding complications.

Results: Data from 3 randomized clinical trials involving 3943 patients were included (2457 men [62.3%]; mean [SD] age ranging from 75.7 [9.3] years to 81.4 [4.3] years per trial subgroup). Coronary intervention with DESs reduced the rates for major adverse cardiac events (OR, 0.68 [95% CI, 0.57-0.82]; P < .001), target lesion revascularization (OR, 0.38 [95% CI, 0.22-0.67]; P = .001), target vessel revascularization (OR, 0.50 [95% CI, 0.38-0.65]; P < .001), and myocardial infarction (OR, 0.51 [95% CI, 0.31-0.83]; P = .01) compared with BMSs at 1 year. The incidence of stent thrombosis was also lower with DESs compared with BMSs (1.8% vs 2.8%), but this difference was not statistically significant in the random-effects model. Additionally, the 2 stent types did not differ in the risks of all-cause mortality, cardiac mortality, and bleeding.

Conclusions and relevance: In the limited number of randomized clinical trials comparing DESs with BMSs with shortened DAPT durations in patients who have high bleeding risk or are uncertain candidates for prolonged DAPT, coronary intervention with specific DESs optimized for biocompatibility is not only safe but also efficacious, even with only 1 month of DAPT.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Kandzari reports grants and personal fees from Medtronic CardioVascular outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Efficacy End Points of Major Adverse Cardiac Events, Target Lesion Revascularization, and Target Vessel Revascularization
The odds ratio estimate of each study is indicated with a square. The size of the square represents the weight of the corresponding study in the meta-analysis.
Figure 2.
Figure 2.. Efficacy End Points of Myocardial Infarction, All-Cause Mortality, and Cardiac Mortality
The odds ratio estimate of each study is indicated by a square whose size represents the weight that the corresponding study had in the meta-analysis.
Figure 3.
Figure 3.. Safety End Points
Individual and pooled odds ratios for stent thrombosis and bleeding complications. The odds ratio estimate of each study is indicated by a square whose size represents the weight that the corresponding study had in the meta-analysis. BARC bleeding indicates bleeding at Bleeding Academic Research Consortium categories 2 through 5.
See this image and copyright information in PMC

Comment in

References

    1. Palmerini T, Benedetto U, Biondi-Zoccai G, et al. . Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65(23):2496-2507. doi:10.1016/j.jacc.2015.04.017 - DOI - PubMed
    1. Levine GN, Bates ER, Blankenship JC, et al. . 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with st-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235-1250. doi:10.1016/j.jacc.2015.10.005 - DOI - PubMed
    1. Levine GN, Bates ER, Blankenship JC, et al. ; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions . 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-e122. doi:10.1016/j.jacc.2011.08.007 - DOI - PubMed
    1. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. ; BASKET-LATE Investigators . Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584-2591. doi:10.1016/j.jacc.2006.10.026 - DOI - PubMed
    1. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. . Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393-1402. doi:10.1016/S0140-6736(12)60324-9 - DOI - PubMed

Substances